BDSX
$16.59
Biodesix, Inc.
Intraday
Recent News
Biodesix Details Lung Test Momentum, 81% Gross Margin and Growth Plan at Barclays Conference
Biodesix (NASDAQ:BDSX) is focused on developing diagnostic tests intended to improve patient outcomes by answering specific clinical questions, Chief Financial Officer Robin Cowie said at a Barclays event. Commercially, the company’s primary emphasis is lung disease, while its research, development,
Biodesix Details Lung Nodule Growth Plan, Primary Care Push at TD Cowen Healthcare Conference
Biodesix (NASDAQ:BDSX) outlined its current commercial focus, growth priorities, and financial milestones during a presentation at the 46th annual TD Cowen Healthcare Conference, where Chief Financial Officer Robin Cowie discussed the company’s positioning in lung nodule management and its biopharma
How The Biodesix (BDSX) Investment Story Is Shifting After Guidance And New US$30 Target
Biodesix’s latest analyst update trims the fair value estimate from US$35 to US$30, resetting the target level used in the valuation work. Supporters of the new target link it to the recent upgrade to Outperform, 2026 revenue guidance that sits 3% ahead of earlier expectations, and a balance sheet that analysts describe as significantly improved, while skeptics question how durable the recent execution really is. As you read on, you will see how these shifting views can help you track and...
Wall Street Analysts Think Biodesix (BDSX) Could Surge 111.62%: Read This Before Placing a Bet
The mean of analysts' price targets for Biodesix (BDSX) points to an 111.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Are Medical Stocks Lagging Biodesix (BDSX) This Year?
Here is how Biodesix, Inc. (BDSX) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.